Oncogenic BRAFV600E inhibits BIM expression to promote melanoma cell survival
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Summary: Somatic activating mutations of BRAF are the earliest and most common genetic abnormality detected in the genesis of human melanoma. However, the mechanism(s) by which activated BRAF promotes melanoma cell cycle progression and/or survival remain unclear. Here we demonstrate that expression of BIM, a pro‐apoptotic member of the BCL‐2 family, is inhibited by BRAF→MEK→ERK signaling in mouse and human melanocytes and in human melanoma cells. Trophic factor deprivation of melanocytes leads to elevated BIM expression. However, re‐addition of trophic factors or activation of a conditional form of BRAFV600E leads to rapid inhibition of BIM expression. In both cases, inhibition of BIM expression was dependent on the activity of MEK1/2 and the proteasome. Consistent with these observations, pharmacological inhibition of BRAF V600E or MEK1/2 in human melanoma cells (using PLX4720 and CI‐1040 respectively) led to a striking elevation of BIM expression. Re‐activation of BRAF→MEK→ERK signaling led to phosphorylation of BIM‐EL on serine 69 and its subsequent degradation. Interestingly, endogenous expression of BIM in melanoma cells was insufficient to induce apoptosis unless combined with serum deprivation. Under these circumstances, inhibition of BIM expression by RNA interference provided partial protection from apoptosis. These data suggest that regulation of BIM expression by BRAF→MEK→ERK signaling is one mechanism by which oncogenic BRAF V600E can influence the aberrant physiology of melanoma cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The shift of MCL-1 to the more potent activator BIM may account for the observed schedule-dependent cytotoxicity of MCL-1 inhibitors, consistent with the requirement of BIM for apoptosis to BRAF inhibitors60.”
From Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies (2019) · cites this paper as [60]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730 · cited 3×
“Somatic activating mutations in BRAF are detected in approximately 85% of benign melanocytic nevi and 60–70% of all melanomas (Davies et al., 2002; Pollock et al.,2003).”
BackgroundMelanoma biology and new targeted therapy
Gray-Schopfer, V., Wellbrock, C., & Marais, R. (2007) · Nature · doi:10.1038/nature05661 · Cited by 1,371 · cited 8×
“In melanoma cells, pharmacological or genetic inhibition of BRAF inhibits cell proliferation and survival of melanoma cells in vitro (Gray-Schopfer et al., 2007).”
BackgroundResultInfluentialOpposing Effects of Ras on p53
Ries, S., Biederer, C., Woods, D., Shifman, O., Shirasawa, S., Sasazuki, T., McMahon, M., Oren, M., & McCormick, F. (2000) · Cell · doi:10.1016/s0092-8674(00)00123-9 · Cited by 357
Self-citationVerhaegen, M., Bauer, J. A., Martín de la Vega, C., Wang, G., Wolter, K. G., Brenner, J. C., Nikolovska-Coleska, Z., Bengtson, A., Nair, R., Elder, J. T., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1748 · Cited by 140 · cited 1×
“…in melanoma, the combination of both MEK inhibition with the addition of a BH3 mimetic com- pound has been shown more effective than MEK inhibi- tion alone (Verhaegen et al., 2006), suggesting that multiple drugs targeting BCL-2 proteins may be used in successful therapy (Mohammad et al., 2008).”
Background
Cited by
BrafV600E cooperates with Pten loss to induce metastatic melanoma
Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky Jr, W. E., You, M. J., DePinho, R. A., McMahon, M., & Bosenberg, M. (2009) · Nature Genetics · doi:10.1038/ng.356 · Cited by 1,189
Self-citationBoni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C.-N. J., Sloss, C. M., Ferrone, C. R., Flaherty, K. T., Lawrence, D. P., Fisher, D. E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0118 · Cited by 742
Paraiso, K. H. T., Xiang, Y., Rebecca, V. W., Abel, E. V., Chen, Y. A., Munko, A. C., Wood, E., Fedorenko, I. V., Sondak, V. K., Anderson, A. R. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2954 · Cited by 551
Melanoma: from mutations to medicine
Tsao, H., Chin, L., Garraway, L. A., & Fisher, D. E. (2012) · Genes & Development · doi:10.1101/gad.191999.112 · Cited by 496
“…suppression of Smac/DIABLO release from mitochondria (Zhang et al. 2003), expression of anti-apoptotic BCL2 through MITF (McGill et al. 2002), suppression of the proapoptotic protein BAD (Eisenmann et al. 2003), and phosphorylation-sensitive degradation of proapoptotic BIM (Cartlidge et al. 2008).”
Tumour cell survival signalling by the ERK1/2 pathway
Balmanno, K., & Cook, S. J. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.148 · Cited by 484
Metadata
- Authors
- Cartlidge, R. A., Thomas, G. R., Cagnol, S., Jong, K. A., Molton, S. A., Finch, A. J., & McMahon, M.
- Venue
- Pigment Cell & Melanoma Research
- Publisher
- Wiley
- Published
- 2008-09-18
- Volume
- 21
- Issue
- 5
- Pages
- 534-544
- ISSN
- 1755-1471 (ISSN-L)
- 1755-148X
- OpenAlex
- W1821265034
- Cited by
- 116
- References
- 4
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oncogenic BRAFV600E inhibits BIM expression to promote melanoma cell survival. https://app.cochat.ai/papers/10.1111/j.1755-148x.2008.00491.x
- The paper
- Cartlidge, R. A., Thomas, G. R., Cagnol, S., Jong, K. A., Molton, S. A., Finch, A. J., & McMahon, M. (2008). Oncogenic BRAFV600E inhibits BIM expression to promote melanoma cell survival. Pigment Cell & Melanoma Research. https://doi.org/10.1111/j.1755-148x.2008.00491.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.